GRAZAX® trial in the US meets primary endpoint
November 02, 2009 08:44 ET
|
ALK Abello
The investigational sublingual allergy immunotherapy tablet (GRAZAX®) meets
primary endpoint in a study of adult subjects with a history of grass pollen
allergies.
Schering-Plough Corporation, ALK's...
GRAZAX® godkendt som sygdomsmodificerende allergibehandling
September 26, 2009 10:06 ET
|
ALK Abello
Sundhedsmyndighederne i 27 europæiske lande har godkendt GRAZAX® som en
sygdomsmodificerende allergibehandling. GRAZAX® er dermed den eneste godkendte
tabletbehandling mod græspollenallergi med en...
GRAZAX® approved as a disease modifying allergy treatment
September 26, 2009 10:06 ET
|
ALK Abello
Authorities in 27 European countries have approved GRAZAX® as a disease
modifying allergy treatment. GRAZAX® is now the only registered tablet
treatment against grass pollen allergy with documented...
Six-month interim report (Q2) 2009
August 18, 2009 05:58 ET
|
ALK Abello
(unaudited)
Financial performance in the six months ended June 30, 2009
(Comparative figures for the same period last year are shown in brackets)
- Sales growth continued in Q2 and organic growth in...
Delårsrapport første halvår (Q2) 2009
August 18, 2009 05:58 ET
|
ALK Abello
(urevideret)
Økonomiske resultater for perioden
(Sammenligningstal for samme periode sidste år er anført i parentes)
- Salgsvæksten fortsatte i andet kvartal, og den organiske vækst i
vaccinesalget...
Release date of six-month interim report (Q2) 2009 for ALK
August 11, 2009 09:41 ET
|
ALK Abello
On Tuesday, August 18, 2009, ALK releases its interim report for the six months
ended June 30, 2009.
ALK will hold a conference call for analysts and investors that day at 2.30
p.m. (CET) at which...
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2009 for ALK
August 11, 2009 09:41 ET
|
ALK Abello
Tirsdag den 18. august 2009 offentliggør ALK delårsrapport for første halvår
(Q2) 2009.
ALK afholder samme dag kl. 14.30 (CET) en telefonkonference for analytikere og
investorer, hvor adm. direktør...
Improved quality of life and sustained symptom control of GRAZAX® after completion of treatment (EAACI 2009)
June 08, 2009 06:00 ET
|
ALK Abello
The clinical benefits of ALK's allergy immunotherapy tablet (AIT) for grass
allergy, GRAZAX®, are sustained after completion of treatment. A follow-up
study covering the first year after treatment...
Forbedret livskvalitet og vedvarende symptomdæmpende effekt af GRAZAX® efter afsluttet behandling (EAACI 2009)
June 08, 2009 06:00 ET
|
ALK Abello
Den kliniske effekt af ALKs tabletvaccine mod græsallergi fortsætter efter
afslutning af behandlingen. Et opfølgningsstudie dokumenterer, at
græspollenallergikere behandlet med GRAZAX® opnår...
House dust mite allergy immunotherapy tablet shows highly beneficial results in asthma patients (EAACI 2009)
June 08, 2009 06:00 ET
|
ALK Abello
ALK's house dust mite allergy immunotherapy tablet (AIT) has a significant
positive clinical effect in asthma patients. This is the conclusion from a
large Phase II/III clinical study (MT-02)...